Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Stein

Showing results (21-30 of 67) with videos related to

Pageof 7
Sort By:
JCO Oncology Practice|June 12, 2025
Diabetes and Acute Care Use Among Patients With Metastatic Prostate Cancer Treated With Androgen Receptor Signaling InhibitorsMichael A Liu, Rohit Raghunathan, Karie Runcie, et al.
The Prostate|August 6, 2010
Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignanciesMark Stein, Hongxia Lin, Chandrika Jeyamohan, et al.
Journal of Oncology|May 12, 2011
Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancerHoward Burris, Joe Stephenson, Gregory A Otterson, et al.
Journal of Translational Medicine|February 25, 2010
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899Robert S DiPaola, Yu-Hui Chen, Mark Stein, et al.
Clinical Biochemistry|May 2, 2002
Newborn thyroxine levels and childhood ADHDOffie Porat Soldin, Arvind K N Nandedkar, Knoxley M Japal, et al.
Cancer|October 6, 2010
Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinomaBrian I Rini, Mark Stein, Pat Shannon, et al.
Urology|September 17, 2015
Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium StudyUlka Vaishampayan, Daniel Shevrin, Mark Stein, et al.
European Urology|June 14, 2013
Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysisYu-Hsuan Joni Shao, Sung Kim, Dirk F Moore, et al.
Cancer|November 2, 2025
Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitorsMichael A Liu, Rohit Raghunathan, Karie Runcie, et al.
Urologic Oncology|July 26, 2011
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancerGlenn Liu, Yu-Hui Chen, Jill Kolesar, et al.
Pageof 7

Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
JCO Oncology Practice|June 12, 2025
Diabetes and Acute Care Use Among Patients With Metastatic Prostate Cancer Treated With Androgen Receptor Signaling InhibitorsMichael A Liu, Rohit Raghunathan, Karie Runcie, et al.
The Prostate|August 6, 2010
Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignanciesMark Stein, Hongxia Lin, Chandrika Jeyamohan, et al.
Journal of Oncology|May 12, 2011
Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancerHoward Burris, Joe Stephenson, Gregory A Otterson, et al.
Journal of Translational Medicine|February 25, 2010
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899Robert S DiPaola, Yu-Hui Chen, Mark Stein, et al.
Clinical Biochemistry|May 2, 2002
Newborn thyroxine levels and childhood ADHDOffie Porat Soldin, Arvind K N Nandedkar, Knoxley M Japal, et al.
Cancer|October 6, 2010
Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinomaBrian I Rini, Mark Stein, Pat Shannon, et al.
Urology|September 17, 2015
Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium StudyUlka Vaishampayan, Daniel Shevrin, Mark Stein, et al.
European Urology|June 14, 2013
Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysisYu-Hsuan Joni Shao, Sung Kim, Dirk F Moore, et al.
Cancer|November 2, 2025
Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitorsMichael A Liu, Rohit Raghunathan, Karie Runcie, et al.
Urologic Oncology|July 26, 2011
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancerGlenn Liu, Yu-Hui Chen, Jill Kolesar, et al.
Pageof 7